number of downloads : ?
File
language
eng
Attribute
Review
Author
Description
Inhibitors of sodium–glucose cotransporter 2 (SGLT2) have undoubtedly shifted the paradigm for diabetes medicine and research and, especially, diabetic kidney disease (DKD). The pharmacological action of SGLT2 inhibitors is simply the release of glucose into urine; however, precisely how SGLT2 inhibitors contribute to the health of those with diabetes has still not been completely elucidated. Towards this end, the present review provides a novel insight into the action of SGLT2 inhibitors by highlighting a neglected fuel-burning system found in proximal tubular cells—‘glycolysis’. In addition, exploring the details of the molecular mechanisms and clinical biomarkers of the organ protection conferred by SGLT2 inhibitors is now required to prepare for the next stage of clinical diabetes medicine—the ‘post-SGLT2 inhibitor era’.
Subject
Hypoxia-inducible factor
Glycolysis
PKM2
SGLT2
Sirt3
Journal Title
Diabetes & Metabolism
Volume
46
Issue
5
Start Page
353
End Page
361
ISSN
1262-3636
Published Date
2020-09-03
DOI
Publisher
Elsevier Masson SAS
NII Type
Journal Article
Format
PDF
Text Version
著者版
Gyoseki ID
39755
OAI-PMH Set
Faculty of Medicine